Previous Article | Next Article 
Infection and Immunity, February 2001, p. 751-757, Vol. 69, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.751-757.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Commercial Preparations of Lipoteichoic Acid
Contain Endotoxin That Contributes to Activation of Mouse Macrophages
In Vitro
Jian Jun
Gao,1
Qiao
Xue,1
Eleanor G.
Zuvanich,1
Kevin R.
Haghi,1 and
David C.
Morrison1,2,*
Department of Basic Medical Sciences,
University of Missouri-Kansas City,1 and
Saint Luke's Hospital-Kansas City,2
Kansas City, Missouri
Received 9 August 2000/Returned for modification 4 October
2000/Accepted 2 November 2000
 |
ABSTRACT |
Lipoteichoic acids (LTA), cell wall components of gram-positive
bacteria, have been reported to induce various inflammatory mediators
and to play a key role in gram-positive-microbe-mediated septic shock.
In a large number of these studies, investigators used commercially
available LTA purified from a variety of gram-positive bacteria,
including Staphylococcus aureus, Bacillus
subtilis, and Streptococcus sanguis. We report here
that, although these commercially available LTA could be readily shown
to stimulate production of nitric oxide (NO) in RAW 264.7 mouse
macrophages, the activity was dramatically inhibited by polymyxin B, a
relatively specific inhibitor of endotoxin biological activity.
One-step purification of the commercially available S. aureus LTA using hydrophobic interaction chromatography resulted
in two well-separated peak fractions, one highly enriched for LTA and a
second highly enriched for endotoxin. The LTA-enriched fractions did
not induce production of NO in RAW 264.7 macrophages, although they
caused a dose-dependent induction of NO in the presence of low
concentrations of gamma interferon (IFN-
) (which by itself induced
little NO), regardless of the presence of polymyxin B. In contrast, the
endotoxin-enriched fractions by themselves inhibited in high levels of
NO in RAW 264.7 macrophages but activity was almost completely
inhibited in the presence of polymyxin B. Consistent with these
findings, our data also indicate that commercial LTA preparations from
S. aureus, B. subtilis, and S. sanguis were not able to induce NO from
lipopolysaccharide-hyporesponsive C3H/HeJ mouse peritoneal macrophages,
but in the presence of IFN-
, these LTA preparations were able to
induce relatively high levels of NO from C3H/HeJ macrophages. These
results indicate that commercially available LTA can contain
contaminating and potentially significant levels of endotoxin that can
be expected to contribute to the putative macrophage-stimulating
effects of LTA as assessed by NO production. The fact that the purified
LTA, by itself, was not able to induce significant levels of NO
secretion in RAW 264.7 macrophages supports the conclusion that caution
in attributing high-level biological activity to this microbial cell
wall constituent should be exercised.
 |
INTRODUCTION |
Lipoteichoic acids (LTA) are
structural components in the outer walls and the cytoplasmic membranes
of gram-positive bacteria. Recently, an increasing number of reports
have indicated that LTA can function as immune system-stimulating
agents and may play a role in the process of septic shock induced by
gram-positive bacteria (reviewed in reference 18). In this
respect, LTA from a variety of different species of gram-positive
bacteria have been reported to stimulate both murine and human
immune/inflammatory cells to produce cytokines, including interleukin-1
(IL-1) (3, 16, 22), tumor necrosis factor alpha (TNF-
)
(3, 22), IL-6 (3), IL-8 (19),
IL-12 (4), and macrophage inflammatory protein-1 alpha
(5). In addition, LTA have also been shown to stimulate
murine macrophages to produce nitric oxide (NO) (9, 11),
which most likely occurs as the result of induced production of the
inducible NO synthase gene (2, 9, 14). Induction of NO by
LTA has been suggested to involve a molecular pathway similar to that
used by lipopolysaccharide (LPS), which would be initiated by the
binding of LTA to cell surface receptor CD14 (4, 9) and/or
transmembrane receptor Toll-like receptor (Toll-2 in this case [17])
and subsequent activation of transcription factor NF-
B (13,
17). Furthermore, LTA have been reported to mediate delayed
circulatory failure (7) and induce (through synergistic
interaction with another bacterial cell wall component, peptidoglycan)
multiple organ failure and lethal shock in experimental models of
sepsis in rats (6).
In a number of the above reports, investigators used commercial
preparations of LTA purified from various species of gram-positive bacteria to conduct their experimental studies. We have recently undertaken similar studies of NO induction in mouse macrophage-like cell line RAW 264.7 using similar commercial preparations of LTA purified from Staphylococcus aureus, Bacillus
subtilis, and Streptococcus sanguis. Although we were
able to reproduce the earlier-reported LTA-induced NO production, we
also observed that the LTA-induced production of NO was dramatically
inhibited by polymyxin B, a relatively specific inhibitor of endotoxin.
While it is possible that, like LPS, LTA binds to polymyxin B, we also
considered that the LTA might be contaminated with small amounts of
biologically active endotoxin. To explore this possibility,
purification of the commercially available S. aureus LTA was
carried out using an octyl-Sepharose column. This procedure resulted in
elution of two well-separated peaks, an LTA-enriched peak and an
endotoxin-enriched peak. Contrary to previously reported studies, we
found that the LTA peak fractions did not induce NO production in RAW
264.7 macrophages unless gamma interferon (IFN-
) was present.
However, the endotoxin peak fractions induced high levels of NO
production, which was virtually totally inhibited by polymyxin B. In
agreement with the above studies, our results also indicate that none
of the commercial LTA preparations from S. aureus, B. subtilis, or S. sanguis was able to induce NO
production from peritoneal macrophages isolated from LPS-hyporesponsive
C3H/HeJ mice, even though, together with IFN-
, these LTA
preparations induced relatively high levels of NO from these cells.
Collectively, our data indicate that commercially available LTA can
contain contaminating detectable levels of endotoxin, which contributes
to at least some of the observed biological activities of LTA.
Therefore, purification of the commercially available LTA appears to be
a necessary preparatory step before undertaking comprehensive
experimental studies to assess the biological potential of such materials.
 |
MATERIALS AND METHODS |
Materials.
LTA, partially purified from S. aureus, B. subtilis, and S. sanguis, was
purchased from Sigma (St. Louis, Mo.). Two different lots of the same
preparations of LTA were used in these studies. Polymyxin B was
purchased from Pfizer-Roerig (New York, N.Y.). Octyl-Sepharose was also
purchased from Sigma.
Cell culture.
Female C3H/HeJ mice from the Jackson
Laboratory (Bar Harbor, Maine) were used at 6 to 8 weeks. Mice were
injected intraperitoneally with 1.5 ml of 4% Brewer thioglycolate
(Difco, Detroit, Mich.), and peritoneal macrophages were harvested 5 days later by lavage with RPMI 1640 culture medium (Life Technologies,
Grand Island, N.Y.). Both C3H/HeJ peritoneal macrophages and the murine
macrophage-like cell line RAW 264.7 (American Type Culture Collection)
were cultured in RPMI 1640 tissue culture medium supplemented with 100 U of penicillin/ml, 100 µg of streptomycin/ml, and 10%
heat-inactivated fetal bovine serum (endotoxin content of less than
0.06 ng/ml; Sigma) at 37°C in a humidified, 5% CO2
environment. In experiments involving macrophage activation,
macrophages were plated at 5 × 104 cells/well in
96-well plates and cultured for 24 h until they reached
confluence. They were then incubated with culture medium containing LTA
or other activators for 20 h, at which time aliquots of the
culture supernatants were assayed for the presence of nitrite (as a
measure of NO production).
LTA purification.
S. aureus LTA, purchased from
Sigma, was further purified essentially as described by Kengatharan et
al. (12). Briefly, LTA was dissolved in equilibration
buffer (0.1 M sodium acetate [pH 4.7], 15% [vol/vol] propan-1-ol)
and applied to an octyl-Sepharose column (CL-4B; 2.5 by 18 cm). The
column was washed with at least three column volumes of equilibration
buffer, and LTA was then eluted using a linear gradient of propan-1-ol
(15 to 100% in equilibration buffer). Fractions of 2.0 ml were
collected, and concentrations of propan-1-ol were estimated by
measurement of refractive index. The fractions were dialyzed
extensively against endotoxin-free distilled water, lyophilized, and
resuspended in 1 ml of endotoxin-free distilled water.
LAL assay.
The relative endotoxin levels in column elute
fractions were determined using Limulus amebocyte lysate
(LAL) test kits purchased from Bio Whittaker (Walkersville, Md.). The
manufacturer's protocol was followed exactly for the assay.
Phosphate assay.
The phosphate content of the eluted column
fractions was determined using a protocol modified from that originally
described by Ames (1). Briefly, to each Pyrex test tube
(13 by 100 mm) containing an aliquot of 20 µl of each column elute
sample, 20 µl of 10% Mg(NO3)2 · H2O (in ethanol) was added. The mixture was evaporated to
dryness by heating the test tube over a flame. Subsequently, 0.45 ml of
1.0 N HCl was added to the tube and the samples were hydrolyzed at
100°C for 15 min to generate inorganic phosphate. Freshly prepared
10% ascorbic acid (1.0 ml)-0.42% ammonium molybdate (1:6
[vol/vol]) was then added, the mixture was incubated at 37°C for 60 min, and absorbance at 820 nm was then determined
spectrophotometrically. Phosphate concentrations were calculated by
comparison against a standard curve generated using sodium phosphate
monohydrate (NaH2PO4 · H2O).
Nitrite assays.
NO in cell culture supernatants was measured
as the concentration of nitrite, a stable reaction product of NO with
molecular oxygen, using the Griess reagent, exactly as previously
described (20). Absorbance (at 570 nm) was determined
using a Dynatech MR5000 microtiter plate reader. Nitrite concentrations
were calculated by comparison with a standard curve generated using
sodium nitrite dissolved in culture medium. All data for nitrite
represent the averages of triplicate samples. Each experiment was
repeated at least two times.
 |
RESULTS |
Induction of NO by commercially available LTA.
Since various
types of LTA have been reported to stimulate NO production in in vitro
cultures of mouse macrophages, rat macrophages, and vascular smooth
muscle cells (2, 9, 11), we tested whether commercially
available LTA extracted from S. aureus, B. subtilis, or S. sanguis would also be able to induce
the mouse macrophage-like cell line RAW 264.7 to produce NO. These
preliminary studies were carried out preparatory to more comprehensive
studies designed to evaluate the consequences to macrophage activation in response to a variety of microbial stimuli. The results of these
experiments essentially confirmed earlier published reports in that
increasing doses of LTA also induced increasing amounts of NO
production in macrophages. As indicated by the data in Fig. 1, although all three types of commercial
LTA preparations were able to induce NO production from RAW 264.7 macrophages, S. sanguis LTA induced much lower levels of NO
than S. aureus and B. subtilis LTA. At relatively
low concentrations (1 to 3 µg/ml), S. aureus and B. subtilis LTA induced 2 to 8 µM NO from macrophages, while S. sanguis LTA induced less than 1 µM NO. At higher
concentrations (10 to 30 µg/ml), S. aureus and B. subtilis LTA induced at least 10 to 18 µM NO from RAW 264.7 macrophages, while S. sanguis LTA induced less than 5 µM
NO.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Induction of NO by commercial preparations of S. aureus, B. Subtilis, and S. sanguis LTA in
RAW 264.7 macrophages. RAW 264.7 macrophages were stimulated with
increasing concentrations of S. aureus, B. subtilis, and S. sanguis LTA for 20 h before
supernatants were taken for nitrite assay as described in Materials and
Methods. Results represent averages of triplicate determinations ± standard errors of the means from one representative experiment
repeated three times under equivalent conditions.
|
|
In order to assess whether such NO-inducing activity would be specific
to LTA, we tested whether polymyxin B, a relatively specific endotoxin
inhibitor, would inhibit the LTA-induced production of NO in RAW 264.7 macrophages. Somewhat unexpectedly, virtually all of the NO production
induced by all three types of LTA was abrogated in the presence of 10 µg of polymyxin B/ml at low LTA concentrations (Fig.
2). At higher LTA concentrations (10 to
30 µg/ml), polymyxin B inhibited greater than 80% of NO production. These findings support the hypothesis that either the commercially available LTA contain relevant amounts of biologically active contaminating endotoxin or that LTA, like LPS, is able to bind polymyxin B.



View larger version (49K):
[in this window]
[in a new window]
|
FIG. 2.
Induction of NO by commercially available S. aureus, B. subtilis, and S. sanguis LTA in
the presence of polymyxin B. RAW 264.7 macrophages were stimulated with
increasing concentrations of S. aureus (A), B. subtilis (B), and S. sanguis (C) LTA in either the
absence (solid columns) or the presence (hatched columns) of 10 µg of
polymyxin B (PMB)/ml for 20 h before supernatants were taken for a
nitrite assay as described in Materials and Methods. Cell viability was
not affected by treatment with LTA either alone or in combination with
polymyxin B, as judged by more than 95% cellular exclusion of trypan
blue in parallel cultures. Data represent averages of triplicate
samples ± standard errors of the means. Experiments were repeated
three times under equivalent conditions.
|
|
Purification of commercially available S. aureus
LTA.
In light of the above results, we initiated experiments to
further purify these preparations of LTA using an octyl-Sepharose column. For this purpose, S. aureus LTA was applied to an
octyl-Sepharose affinity column and fractions were eluted and treated
as described in Materials and Methods using a linear gradient of
propan-1-ol. Each column fraction was then tested for phosphate content
in order to monitor the elution of LTA, since LTA is known to contain a
significant amount of phosphate (12). Each eluted fraction was also assayed for endotoxin content using the LAL test to monitor the presence of endotoxin. As shown by the results of these assays (Fig. 3A), a relatively minor peak of
phosphate-containing material, which did not correspond to the
anticipated abundance of LTA, was detected in fractions 25 to 35, whereas factions 41 to 47 contained a large amount of phosphate. Since
this elution profile corresponds exactly with the previously reported
elution concentration of propan-1-ol, these results strongly suggest
that fractions 41 to 47 are the major peak of LTA (12).
When all of the affinity column-eluted fractions were subjected to LAL
assay, only a minimal amount of LAL activity was detected in fractions
41 to 47, which as pointed out above correspond to the major LTA peak.
However, in fractions 48 to 54, a substantial amount of LAL activity
(corresponding to approximately 680 endotoxin units/ml in fraction 50)
was detected (Fig. 3A). As expected, the endotoxin levels in fractions
48 to 54 detected by LAL assay were dramatically reduced in the
presence of polymyxin B (Fig. 3A). These results strongly support the
conclusions that, (i) the commercially available S. aureus
LTA contains a significant amount of LAL-reactive endotoxin and (ii)
the LAL-reactive biologically active constituent is readily
separable from high-phosphate-containing LTA using octyl-Sepharose
affinity chromatography.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Purification of commercially available S. aureus LTA. LTA was purified with an octyl-Sepharose column
as described in Materials and Methods. The column was successfully
eluted with a linear gradient of 15 to 80% propan-1-ol in
equilibration buffer (dashed line). Fractions of 2 ml were collected,
dialyzed, lyophilized, and resuspended in endotoxin-free water and
tested for phosphate content as described in Materials and Methods. The
same fractions were also subjected to an LAL assay to test endotoxin
levels either in the absence (solid triangles) or the presence (open
triangles) of 10 µg of polymyxin B (PMB)/ml. Data represent averages
of duplicate samples. Experiments were repeated two times. (B)
Induction of NO by eluted LTA fractions. Macrophages were stimulated
with different LTA fractions (1:33 dilution in culture medium) for
20 h in either the absence (solid circles) or the presence (open
circles) of 10 µg of polymyxin B/ml before supernatants were
harvested for a nitrite assay as described in Materials and Methods.
Data represent averages of triplicate samples. Experiments were
repeated two times under equivalent conditions.
|
|
Induction of NO by eluted S. aureus LTA fractions.
In order to further explore which of the two constituents present in
the original S. aureus LTA identified in the octyl-Sepharose elution profile is responsible for the observed secretion of NO from
RAW 264.7 macrophages (Fig. 1), RAW 264.7 macrophages were cultured in
vitro with aliquots of the eluted column fractions and subsequently
assayed for NO production present in culture supernatants. As shown by
the data in Fig. 3B, fractions 41 to 47, which correspond to the major
LTA peak, did not induce any detectable NO production. In other
experiments, LTA purified by affinity chromatography and used at
concentrations as high as 100 µg/ml were also not able to induce any
observable NO production in RAW 264.7 macrophages (data not shown). In
contrast, fractions 48 to 54, which correspond to the LAL-reactive
endotoxin peak, initiated significant induction of NO. Furthermore, NO
secretion in response to the biologically active material present in
fractions 48 to 54 (LAL reactive) was almost completely abrogated in
the presence of endotoxin-specific inhibitor polymyxin B.
We also investigated the potential biological activity of a combination
of LTA-enriched fractions and endotoxin-enriched fractions to stimulate
NO production in cultures of macrophages. The LTA-enriched fractions
neither increased nor inhibited NO production induced by the
endotoxin-enriched fractions (data not shown), suggesting that the NO
induction by the commercially available S. aureus LTA
observed in Fig. 1 is not the result of the synergistic interaction of
its endotoxin and LTA components. These data strongly suggest that it
is the LAL-reactive endotoxin component, rather than the LTA component,
in the commercially available S. aureus LTA that contributes
to induction of NO production in the RAW 264.7 macrophage-like cell line.
Induction of NO by purified S. aureus LTA in the
presence of IFN-
.
The data shown in Fig. 3 indicate that
purified S. aureus LTA was not able to induce NO production
in RAW 264.7 macrophages, strongly suggesting that it is the
contaminating endotoxin component that contributes to the observed
biological activity of commercial preparations of S. aureus
LTA. While this conclusion is supported by the evidence presented
above, these data do not completely exclude the possibility that the
lack of NO induction by purified S. aureus LTA might be the
result of a loss of biological activity during the purification
process. In order to address this possibility, studies to evaluate
whether or not the purified S. aureus LTA had any biological
activity were carried out. Since it has been reported that IFN-
can
synergize with LTA to induce NO production from a variety of cell types
(8, 10), we examined whether the column-purified LTA is
able to induce NO from RAW 264.7 macrophages in the presence of
IFN-
. As shown by the data in Fig. 4,
while the purified S. aureus LTA alone did not induce
production of NO, it caused a significant induction of NO in the
presence of 30 U of IFN-
/ml (which by itself induced only low levels
of NO production). Of particular interest is that the NO induced by purified LTA plus IFN-
was not significantly inhibited by polymyxin B at a concentration of 10 µg/ml (Fig. 4).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of NO by column-purified S. aureus
LTA in the presence of IFN- . RAW 264.7 macrophages were
incubated with increasing concentrations of purified S. aureus LTA either in the absence (circles) or presence (triangles)
of 10 U of IFN- /ml for 20 h before culture supernatants were
collected for a nitrite assay as described in Materials and Methods. To
test whether the purified LTA-IFN- -induced NO can be inhibited by
polymyxin B (PMB), 10 µg of polymyxin B/ml was included in the
treating mixture (squares). Results represent averages of triplicate
samples ± standard errors of the means. Experiments were repeated
three times.
|
|
In combination with the data in Fig. 1, these results indicate that (i)
the inability of purified S. aureus LTA to induce NO was not
caused by a loss of biological activity during the purification process
and (ii) inhibition of the unpurified commercial S. aureus
LTA-induced NO by polymyxin B (Fig. 2A) was not due to a direct
inhibitory effect of polymyxin B on the LTA component. Therefore, these
findings further support the conclusion that it is the contaminating
endotoxin component in commercial S. aureus LTA that
contributes the NO-inducing activity in RAW 264.7 macrophages.
Induction of NO from C3H/HeJ peritoneal macrophages by unpurified
commercial LTA with or without IFN-
.
As an alternative approach
to evaluate the intrinsic biological activity of the LTA component
alone in the unpurified commercial preparations of LTA, we treated
peritoneal macrophages isolated from the LPS-hyporesponsive C3H/HeJ
mouse strain with commercial preparations of LTA from S. aureus, B. subtilis, or S. sanguis. Since it
is well recognized that C3H/HeJ macrophages do not respond to LPS
(21, 23), it was anticipated that the unpurified
commercial preparations of LTA would be incapable of stimulating
C3H/HeJ macrophages to produce NO even in the presence of a significant amount of contaminating endotoxin. As shown by the data in Fig. 5, neither S. aureus LTA,
B. subtilis LTA, nor S. sanguis LTA alone was
able to stimulate NO production from C3H/HeJ peritoneal macrophages
even at the highest level tested, 30 µg/ml (data not shown). However,
in the presence of IFN-
, all three species of LTA were able to
induce NO production from C3H/HeJ macrophages. Interestingly, while
unpurified preparations of S. aureus LTA and B. subtilis LTA induced about equivalent NO production from RAW 264.7 macrophages (Fig. 1), the former (in the presence of IFN-
) induced
much lower levels of NO from C3H/HeJ macrophages (Fig. 5). The NO
levels induced by S. sanguis LTA plus IFN-
from C3H/HeJ
macrophages are about equivalent to those induced by S. sanguis LTA in RAW 264.7 macrophages. These data indicate that the
LTA component alone in commercial LTA preparations is not sufficient to
induce NO production from mouse macrophages. However, in the presence
of IFN-
, LTA is able to induce NO production from LPS-hyporesponsive
mouse macrophages. These findings further support the conclusion that
it is the contaminating endotoxin that contributes to the NO-inducing
activity of commercial LTA from LPS-responsive mouse RAW 264.7 macrophages.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Induction of NO by commercial LTA preparations from
C3H/HeJ peritoneal macrophages. C3H/HeJ macrophages were treated with
increasing concentrations of S. aureus, B. subtilis, and S. sanguis LTA in the presence of 30 U of
IFN- /ml for 20 h. Culture supernatants were then collected for
a nitrite assay as described in Materials and Methods. Data represent
averages of triplicate samples ± standard errors of the mean.
Experiments were repeated three times. None of the three types of
commercial LTA alone induced detectable NO production (data not shown).
|
|
 |
DISCUSSION |
Collectively, the data presented in this paper indicate that
commercially available LTA extracted from S. aureus,
B. subtilis, and S. sanguis can be demonstrated
to contain significant amounts of biologically active endotoxin
contaminants that contribute to biological activity as assessed by in
vitro macrophage activation studies. Purification of at least one of
these commercial LTA preparations (S. aureus LTA) using an
octyl-Sepharose column resulted in an LTA-enriched peak and an
endotoxin-enriched peak. Although the fractions corresponding to the
LAL-reactive endotoxin peak induced NO production from RAW 264.7 macrophages, fractions from the LTA peak were not able to induce NO
from RAW 264.7 macrophages (Fig. 3B). This inability of purified LTA to
induce NO production was not the result of loss of activity of LTA
during the process of purification, since, in the presence of low
concentrations of IFN-
, purified S. aureus LTA was able
to stimulate macrophages to produce high levels of NO (Fig. 4).
Purified S. aureus LTA alone was also able to induce
relatively high levels of TNF-
in RAW 264.7 macrophages (e.g., 10 µg of LTA/ml for about 13,600 pg of TNF-
/ml). Of additional
importance is the fact that, in contrast to that of LPS, the biological
activity of endotoxin-free S. aureus LTA in the presence of
IFN-
in RAW 264.7 macrophages was not significantly inhibited by
polymyxin B (Fig. 4). This finding lends support to the conclusion that
the inhibitory effect of polymyxin B on commercial preparations of
S. aureus LTA is not due to its binding to and inhibition of
the LTA component. In agreement with the above findings, none of the
commercial LTA preparations from S. aureus, B. subtilis, and S. sanguis induced NO production from
LPS-hyporesponsive C3H/HeJ peritoneal macrophages, although together
with IFN-
each of the three commercial LTA preparations was able to
induce significant levels of NO production (Fig. 5). Taken together,
these data allow the conclusion that commercially available LTA can be
contaminated with a significant amount of biologically active
endotoxin, which contributes to the observed NO induction from RAW
264.7 macrophages by such preparations. More importantly, our results
also indicate that the endotoxin component in commercially available
S. aureus LTA could be separated by hydrophobic interaction
chromatography using an octyl-Sepharose column (Fig. 3A). This will
provide investigators a necessary but relatively straightforward means
for purification of commercially available LTA preparations in studies
involving LTA.
Our findings reported here also raise the possibility that the
induction of NO as well as other inflammatory mediators by commercially
available LTA in various types of cells reported in some previously
published studies may be, at least in part, due to endotoxin
contamination. One of the primary pieces of supportive evidence is the
fact that, in the present study, commercial preparations of S. aureus LTA subjected to additional purification steps were not
able to induce NO production in RAW 264.7 macrophages (Fig. 3B) in the
absence of the supplemental costimulator. Another important piece of
evidence supporting this conclusion is results of studies showing that
commercial preparations of LTA are biologically inert in the induction
of NO secretion from LPS-hyporesponsive C3H/HeJ macrophages.
Further supportive evidence includes recent studies from two other
groups. Keller et al. (11) reported that, although
purified S. aureus LTA retains the ability to stimulate rat
bone marrow-derived macrophages to produce modest levels of TNF-
, it
failed to induce NO production. Moreover, Bhakdi et al.
(3) showed that purified LTA from S. aureus
failed to stimulate human monocytes to produce IL-1 and IL-6. However,
the latter authors also reported that purified S. aureus LTA
was unable to induce TNF-
production in human monocytes, a finding
that conflicts with observations by Keller et al. (11) and
our laboratory. Whether this discrepancy is due to distinct responses
in different cell types is not known. Nevertheless, all of these
studies support the notion that contaminating endotoxin in commercially
available LTA preparations can and does contribute significantly to the
observed biological activity of LTA, even though the role of pure LTA
alone in inflammatory cell activation cannot be overlooked. Also worthy
of note is a recent report by English et al. (8). In those
studies, commercially available LTA from gram-positive bacteria
S. sanguis and Streptococcus mutans were shown to
induce TNF-
and NO production from RAW 264.7 macrophages. However,
induction of TNF-
and NO by these two types of LTA was significantly
reduced by treatment with polymyxin B. Together with our studies on
S. aureus, B. subtilis, and S. sanguis LTA, these findings suggest once again that commercially available LTA
extracts of gram-positive bacteria may contain endotoxin contaminants.
It would be of interest to speculate on the possible origin of the
contaminating endotoxin, particularly given that fact that the
microbial sources of the three commercial preparations of LTA used in
these studies were all from gram-positive organisms. However, in the
present study, LTA concentrations of about 10 µg/ml were usually
required to generate significant levels of NO secretion in cultures of
RAW 264.7 macrophages, and previously published reports from several
laboratories have confirmed that endotoxin at the level of 100 pg/ml
can manifest biological activity in these cells. Thus, levels of
contamination of only 1 part in 105 would be sufficient to
generate levels of endotoxin contamination adequate to explain the
resulting macrophage responses.
In summary, the data presented in this report indicate that
commercially available LTA contains significant amounts of endotoxin, which contributes to the observed biological activities of LTA such as
NO induction. The contaminating endotoxin component is separable from
LTA by hydrophobic interaction chromatography. Since endotoxin is
reportedly not a structural component of gram-positive bacteria
(15, 24), the source of the contamination is not known.
However, regardless of the source of endotoxin contamination, purification of commercially available LTA before using it for both in
vitro and in vivo studies is highly necessary.
 |
ACKNOWLEDGMENTS |
We thank Christopher Papasian, Alexander Shnyra, and Mei-Guey Lei
for their constructive advice and Kathy Rode for her administrative assistance in the process of manuscript preparation.
This research was supported by National Institutes of Health grants
AI-23447 and AI-44936, the Kansas Health Foundation, the Saint Luke's
Hospital Foundation, and an unrestricted medical research grant from
Merck & Co., West Point, Pa. David C. Morrison was supported in part by
the Westport Anesthesia Services/State of Missouri Endowed Chair in Research.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Office of
Research Administration, Room 3112 Main Hospital, Saint Luke's
Hospital of Kansas City, 4401 Wornall Rd., Kansas City, MO 64111. Phone: (816) 932-9844. Fax: (816) 932-6091. E-mail:
dmorrison{at}saint-lukes.org.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Ames, B. N.
1966.
Assay of inorganic phosphate, total phosphate and phosphatases.
Methods Enzymol.
3:115-118.
|
| 2.
|
Auguet, M.,
M. O. Lonchampt,
S. Delaflotte,
J. Goulin-Schulz,
P. E. Chabrier, and P. Braquet.
1992.
Induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in vascular smooth muscle cells.
FEBS Lett.
297:183-185[CrossRef][Medline].
|
| 3.
|
Bhakdi, S.,
T. Klonisch,
P. Nuber, and W. Fischer.
1991.
Stimulation of monokine production by lipoteichoic acids.
Infect. Immun.
59:4614-4620[Abstract/Free Full Text].
|
| 4.
|
Cleveland, M. G.,
J. D. Gorham,
T. L. Murphy,
E. Tuomanen, and K. M. Murphy.
1996.
Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway.
Infect. Immun.
64:1906-1912[Abstract].
|
| 5.
|
Danforth, J. M.,
R. M. Strieter,
S. L. Kunkel,
D. A. Arenberg,
G. M. VanOtteren, and T. J. Standiford.
1995.
Macrophage inflammatory protein-1 alpha expression in vivo and in vitro: the role of lipoteichoic acid.
Immunol. Immunopathol.
74:77-83.
|
| 6.
|
De-Kimpe, S. J.,
M. Kengatharan,
C. Thiemermann, and J. R. Vane.
1995.
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.
Proc. Natl. Acad. Sci. USA
92:10359-10363[Abstract/Free Full Text].
|
| 7.
|
De-Kimpe, S. J.,
M. L. Hunter,
C. E. Bryant,
C. Thiemermann, and J. R. Vane.
1995.
Delayed circulatory failure due to the induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in anaesthetized rats.
Br. J. Pharmacol.
114:1317-1323[Medline].
|
| 8.
|
English, B. K.,
C. C. Patrick,
S. L. Orlicek,
R. McCordic, and J. L. Shenep.
1996.
Lipoteichoic acid from viridans streptococci induces the production of tumor necrosis factor and nitric oxide by murine macrophages.
J. Infect. Dis.
174:1348-1351[Medline].
|
| 9.
|
Hattor, Y.,
K. Kasai,
K. Akimoto, and C. Thiemermann.
1997.
Induction of NO synthesis by lipoteichoic acid from Staphylococcus aureus in J774 macrophages: involvement of a CD14-dependent pathway.
Biochem. Biophys. Res. Commun.
233:375-376[CrossRef][Medline].
|
| 10.
|
Hattori, Y.,
K. Kasai,
N. Nakanishi,
S. S. Gross, and C. Thiemermann.
1998.
Induction of nitric oxide and tetrahydrobiopterin synthesis by lipoteichoic acid from Staphylococcus aureus in vascular smooth muscle cells.
J. Vasc. Res.
35:104-108[CrossRef][Medline].
|
| 11.
|
Keller, R.,
W. Fischer,
R. Keist, and S. Bassetti.
1992.
Macrophage response to bacteria: induction of marked secretory and cellular activities by lipoteichoic acids.
Infect. Immun.
60:3664-3672[Abstract/Free Full Text].
|
| 12.
|
Kengatharan, K. M.,
S. De-Kimpe,
C. Robson,
S. J. Foster, and C. Thiemermann.
1998.
Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure.
J. Exp. Med.
188:305-315[Abstract/Free Full Text].
|
| 13.
|
Kengatharan, M.,
S. J. De-Kimpe, and C. Thiemermann.
1996.
Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages.
Br. J. Pharmacol.
117:1163-1170[Medline].
|
| 14.
|
Lonchampt, M. O.,
M. Auguet,
S. Delaflotte,
J. Goulin-Schulz,
P. E. Chabrier, and P. Braquet.
1992.
Lipoteichoic acid: a new inducer of nitric oxide synthase.
J. Cardiovasc. Pharmacol.
12(Suppl.):S145-S147.
|
| 15.
|
Natanson, C.,
R. L. Danner,
R. J. Elin,
J. M. Hosseini,
K. W. Peart,
S. M. Banks,
T. J. MacVittie,
R. I. Walker, and J. E. Parrillo.
1989.
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock J.
Clin. Investig.
83:243-251. (Erratum, 83:1087.)
|
| 16.
|
Riesenfeld-Om, I.,
S. Wolpe,
J. F. Garcia-Bustos,
M. K. Hoffmann, and E. Tuomanen.
1989.
Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components.
Infect. Immun.
57:1890-1893[Abstract/Free Full Text].
|
| 17.
|
Schwandner, R.,
R. Dziarski,
H. Wesche,
M. Rothe, and C. J. Kirschning.
1999.
Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2.
J. Biol. Chem.
274:17406-17409[Abstract/Free Full Text].
|
| 18.
|
Sriskandan, S., and J. Cohen.
1999.
Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis.
Infect. Dis. Clin. N. Am.
13:397-412[CrossRef][Medline].
|
| 19.
|
Standiford, T. J.,
D. A. Arenberg,
J. M. Danforth,
S. L. Kunkel,
G. M. VanOtteren, and R. M. Strieter.
1994.
Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytes: a cellular and molecular analysis.
Infect. Immun.
62:119-125[Abstract/Free Full Text].
|
| 20.
|
Stuehr, D. J., and C. F. Nathan.
1989.
Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.
J. Exp. Med.
169:1543-1555[Abstract/Free Full Text].
|
| 21.
|
Sultzer, B. M.
1968.
Endotoxin-induced resistance to a staphylococcal infection: cellular and humoral responses compared in two mouse strains.
J. Infect. Dis.
118:340[Medline].
|
| 22.
|
Tsutsui, O.,
S. Kokeguchi,
T. Matsumura, and K. Kato.
1991.
Relationship of the chemical structure and immunobiological activities of lipoteichoic acid from Streptococcus faecalis (Enterococcus hirae) ATCC 9790.
FEMS. Microbiol. Immunol.
3:211-218[Medline].
|
| 23.
|
Vogel, S. N.,
N. Bhat,
S. T. Qureshi, and D. Malo.
1999.
Genetic control of endotoxin responsiveness: the Lps gene revisited, p. 735-750.
In
D. C. Morrison, H. Brade, S. M. Opal, and S. N. Vogel (ed.), Endotoxin in health and disease. Marcel Dekker, New York, N.Y.
|
| 24.
|
Wakabayashi, G.,
J. A. Gelfand,
W. K. Jung,
R. J. Connolly,
J. F. Burke, and C. A. Dinarello.
1991.
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.
J. Clin. Investig.
87:1925-1935.
|
Infection and Immunity, February 2001, p. 751-757, Vol. 69, No. 2
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.2.751-757.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Seo, H. S., Michalek, S. M., Nahm, M. H.
(2008). Lipoteichoic Acid Is Important in Innate Immune Responses to Gram-Positive Bacteria. Infect. Immun.
76: 206-213
[Abstract]
[Full Text]
-
Mullaly, S. C., Kubes, P.
(2006). The Role of TLR2 In Vivo following Challenge with Staphylococcus aureus and Prototypic Ligands. J. Immunol.
177: 8154-8163
[Abstract]
[Full Text]
-
Mueller, M., Stamme, C., Draing, C., Hartung, T., Seydel, U., Schromm, A. B.
(2006). Cell Activation of Human Macrophages by Lipoteichoic Acid Is Strongly Attenuated by Lipopolysaccharide-binding Protein. J. Biol. Chem.
281: 31448-31456
[Abstract]
[Full Text]
-
Hasty, D. L., Meron-Sudai, S., Cox, K. H., Nagorna, T., Ruiz-Bustos, E., Losi, E., Courtney, H. S., Mahrous, E. A., Lee, R., Ofek, I.
(2006). Monocyte and Macrophage Activation by Lipoteichoic Acid Is Independent of Alanine and Is Potentiated by Hemoglobin. J. Immunol.
176: 5567-5576
[Abstract]
[Full Text]
-
Traub, S., von Aulock, S., Hartung, T., Hermann, C.
(2006). Invited review: MDP and other muropeptides direct and synergistic effects on the immune system. Innate Immunity
12: 69-85
[Abstract]
-
Yang, J. S., Kim, H. J., Ryu, Y. H., Yun, C.-H., Chung, D. K., Han, S. H.
(2006). Endotoxin contamination in commercially available pokeweed mitogen contributes to the activation of murine macrophages and human dendritic cell maturation.. CVI
13: 309-313
[Abstract]
[Full Text]
-
Han, S. H., Kim, J. H., Seo, H. S., Martin, M. H., Chung, G.-H., Michalek, S. M., Nahm, M. H.
(2006). Lipoteichoic Acid-Induced Nitric Oxide Production Depends on the Activation of Platelet-Activating Factor Receptor and Jak2. J. Immunol.
176: 573-579
[Abstract]
[Full Text]
-
Brun, P., Castagliuolo, I., Pinzani, M., Palu, G., Martines, D.
(2005). Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol.
289: G571-G578
[Abstract]
[Full Text]
-
Fournier, B., Philpott, D. J.
(2005). Recognition of Staphylococcus aureus by the Innate Immune System. Clin. Microbiol. Rev.
18: 521-540
[Abstract]
[Full Text]
-
Henneke, P., Morath, S., Uematsu, S., Weichert, S., Pfitzenmaier, M., Takeuchi, O., Muller, A., Poyart, C., Akira, S., Berner, R., Teti, G., Geyer, A., Hartung, T., Trieu-Cuot, P., Kasper, D. L., Golenbock, D. T.
(2005). Role of Lipoteichoic Acid in the Phagocyte Response to Group B Streptococcus. J. Immunol.
174: 6449-6455
[Abstract]
[Full Text]
-
Kim, J. H., Seo, H., Han, S. H., Lin, J., Park, M.-K., Sorensen, U. B. S., Nahm, M. H.
(2005). Monoacyl Lipoteichoic Acid from Pneumococci Stimulates Human Cells but Not Mouse Cells. Infect. Immun.
73: 834-840
[Abstract]
[Full Text]
-
Shepherd, E. G., Zhao, Q., Welty, S. E., Hansen, T. N., Smith, C. V., Liu, Y.
(2004). The Function of Mitogen-activated Protein Kinase Phosphatase-1 in Peptidoglycan-stimulated Macrophages. J. Biol. Chem.
279: 54023-54031
[Abstract]
[Full Text]
-
McCaffrey, R. L., Fawcett, P., O'Riordan, M., Lee, K.-D., Havell, E. A., Brown, P. O., Portnoy, D. A.
(2004). From the Cover: A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc. Natl. Acad. Sci. USA
101: 11386-11391
[Abstract]
[Full Text]
-
Neuhaus, F. C., Baddiley, J.
(2003). A Continuum of Anionic Charge: Structures and Functions of D-Alanyl-Teichoic Acids in Gram-Positive Bacteria. Microbiol. Mol. Biol. Rev.
67: 686-723
[Abstract]
[Full Text]
-
Han, S. H., Kim, J. H., Martin, M., Michalek, S. M., Nahm, M. H.
(2003). Pneumococcal Lipoteichoic Acid (LTA) Is Not as Potent as Staphylococcal LTA in Stimulating Toll-Like Receptor 2. Infect. Immun.
71: 5541-5548
[Abstract]
[Full Text]
-
Schroder, N. W. J., Morath, S., Alexander, C., Hamann, L., Hartung, T., Zahringer, U., Gobel, U. B., Weber, J. R., Schumann, R. R.
(2003). Lipoteichoic Acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus Activates Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved. J. Biol. Chem.
278: 15587-15594
[Abstract]
[Full Text]
-
Deininger, S., Stadelmaier, A., von Aulock, S., Morath, S., Schmidt, R. R., Hartung, T.
(2003). Definition of Structural Prerequisites for Lipoteichoic Acid-Inducible Cytokine Induction by Synthetic Derivatives. J. Immunol.
170: 4134-4138
[Abstract]
[Full Text]
-
Vreugdenhil, A. C. E., Rousseau, C. H., Hartung, T., Greve, J. W. M., van 't Veer, C., Buurman, W. A.
(2003). Lipopolysaccharide (LPS)-Binding Protein Mediates LPS Detoxification by Chylomicrons. J. Immunol.
170: 1399-1405
[Abstract]
[Full Text]
-
Takada, H., Yokoyama, S., Shuhua Yang,
(2002). Mini-review: Enhancement of endotoxin activity by muramyldipeptide. Innate Immunity
8: 337-342
[Abstract]
-
UEHARA, A., SUGAWARA, S., TAKADA, H.
(2002). Priming of human oral epithelial cells by interferon-{gamma} to secrete cytokines in response to lipopolysaccharides, lipoteichoic acids and peptidoglycans. J Med Microbiol
51: 626-634
[Abstract]
[Full Text]
-
Morath, S., Stadelmaier, A., Geyer, A., Schmidt, R. R., Hartung, T.
(2002). Synthetic Lipoteichoic Acid from Staphylococcus aureus Is a Potent Stimulus of Cytokine Release. J. Exp. Med.
195: 1635-1640
[Abstract]
[Full Text]
-
Yipp, B. G., Andonegui, G., Howlett, C. J., Robbins, S. M., Hartung, T., Ho, M., Kubes, P.
(2002). Profound Differences in Leukocyte-Endothelial Cell Responses to Lipopolysaccharide Versus Lipoteichoic Acid. J. Immunol.
168: 4650-4658
[Abstract]
[Full Text]
-
Morath, S., Geyer, A., Spreitzer, I., Hermann, C., Hartung, T.
(2002). Structural Decomposition and Heterogeneity of Commercial Lipoteichoic Acid Preparations. Infect. Immun.
70: 938-944
[Abstract]
[Full Text]
-
Yohe, H. C., Wallace, P. K., Berenson, C. S., Ye, S., Reinhold, B. B., Reinhold, V. N.
(2001). The major gangliosides of human peripheral blood monocytes/macrophages: absence of ganglio series structures. Glycobiology
11: 831-841
[Abstract]
[Full Text]